73083-19-9

Upstream product

• 34068-01-4 1-[3-(phenylmethoxy)phenyl]ethan-1-one 
• 105-58-8 Diethyl carbonate 
• 121-71-1 3-Hydroxyacetophenone 
• 100-44-7 benzyl chloride 

Downstream Products

• 94594-70-4 (E)-3-(3-Benzyloxy-phenyl)-3-(2-oxo-3,4-dihydro-2H-quinolin-1-ylamino)-acrylic acid ethyl ester 
• 83391-33-7 (E)-3-(3-Benzyloxy-phenyl)-3-(1-oxo-3,4-dihydro-1H-isoquinolin-2-ylamino)-acrylic acid ethyl ester 
• 867187-68-6 3-(3-benzyloxyphenyl)-N-isopropyl-3-oxopropionamide 
• 947270-86-2 ethyl 2-[3-(benzyloxy)benzoyl]-4-oxopentanoate 
• 701244-25-9 6-(3-benzyloxyphenyl)-2-(morpholin-4-yl)pyrimidin-4(3H)-one 
• 81411-96-3 2-(3-benzyloxy-phenyl)-5,6-dihydro-pyrazolo[5,1-a]isoquinoline-1-carboxylic acid 
• 61001-32-9 2-(3-benzyloxy-phenyl)-5,6-dihydro-pyrazolo[5,1-a]isoquinoline 
• 60230-71-9 2-(m-Benzyloxyphenyl)-4,5-dihydropyrazolo[1,5-a]quinoline 
• 60230-76-4 4,5-dihydro-2(3-n.propyloxyphenyl)pyrazolo<1,5-a>quinoline 
• 61001-34-1 2-(m-ethoxyphenyl)-5,6-dihydro-pyrazolo-<5,1-a>isoquinoline 
• 94594-82-8 4,5-dihydro-2(3-ethoxyphenyl)pyrazolo<1,5-a>quinoline 

Relevant academic research and scientific papers

Synthesis and structure-activity relationship of novel indene N-oxide derivatives as potent peroxisome proliferator activated receptor γ (PPARγ) agonists

A series of novel indene N-oxide derivatives were prepared by various synthetic methods and evaluated for their ability to activate PPARγ. The best PPARγ agonist in this series was 9 h, which showed an EC50 value of 15 nM.

INDENE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF

The inventive indene derivatives of formula (I) are capable of selectively modulating the activities of peroxisome proliferator activated receptors (PPARs), causing no adverse side effects, and thus, they are useful for the treatment and prevention of disorders modulated by PPARs, i.e., metabolic syndromes such as diabetes, obesity, arteriosclerosis, hyperlipidemia, hyperinsulinism and hypertension, inflammatory diseases such as osteoporosis, liver cirrhosis and asthma, and cancer.

2,4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER

Compounds having formula I are provided where the variables have the values described herein. (I). Pharmaceutical formulations include the compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and combinations with other agents. A method of treating a patient comprises administering a pharmaceutical formulation according to the invention to a patient in need thereof.